We are doing this study to test a program that is being developed by nurses to help patients with HER2+ metastatic breast cancer manage their treatment with three drugs typically used for this diagnosis: tucatinib, trastuzumab, and capecitabine. The program's goal is to help patients manage symptoms and provide resources to improve their quality of life.

HER2+ Metastatic Breast Cancer

Women ages 18+ who:

• Are diagnosed with HER2+ metastatic breast cancer
• Are being treated with tucatinib, trastuzumab, and capecitabine

For more information, contact the study team at smrithi.divakaran@duke.edu.

If you choose to participate, we will schedule you to have a one-time interview with a research team member. In this interview, we will ask for your opinions and input about the research team's proposed nurse-led program to support women with HER2+ breast cancer. We will share program details and explain our ideas before asking for your input. The study team will ask you about the content and structure of the program and materials created for patients. We expect that interviews will last about 45 minutes.